Checkpoint Therapeutics, Inc. - CKPT Operating profit EBITDA
Checkpoint Therapeutics is advancing biopharmaceuticals, focusing on the transparent FDA approval process for cosibelimab. The financial EBITDA metric confirms current performance, with the value of the indicator standing at . However, capital deficits and potential test failures create significant risks. The market capture strategy relies on launching the therapy at a substantial discount to the prices of industry leaders.
Checkpoint Therapeutics, Inc. (CKPT) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Checkpoint Therapeutics|CKPT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Checkpoint Therapeutics Inc.|CKPT - Company Aggregate Debts|Debts to Book Value Checkpoint Therapeutics|CKPT - Company Long-Term Debts|Company Current Liabilities Checkpoint Therapeutics|Quick Ratio checkpointtx.com
- earnings and market ratios statistics:
CKPT - Company Net Income|Forward Earnings Checkpoint Therapeutics|CKPT - Price to Earnings Ratio|Projected Price to Earnings Ratio checkpointtx.com|CKPT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Checkpoint Therapeutics|CKPT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Checkpoint Therapeutics|CKPT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months checkpointtx.com|CKPT - Net earnings per share growth this year|Expected earnings per share trend next year Checkpoint Therapeutics
Summary company analytics:Checkpoint Therapeutics
Checkpoint Therapeutics (CKPT) is strengthening its position in oncology by developing affordable antibodies for skin cancer therapy, which is building significant brand trust. An analysis of the company's aggregate EBITDA allows for a comparison of current cash flow with historical data to objectively assess the cost of capital, preventing investments in overvalued assets that occur when retrospection is ignored in favor of short-term trends.
Who Checkpoint Therapeutics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit before deduction of amortization erasca.com ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Income before deduction of interest, taxes and amortization YMAB|Aura Bio - Operating profit EBITDA|Profit before interest, taxes and amortization Candel Therapeutics|ARAY: Operating profit EBITDA|Operating profit before deduction of amortization SELLAS Life Sciences Group|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Operating profit EBITDA Citius Oncology Inc.|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|TARA: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|Aadi Bioscience, Inc. (WHWK) - Profit before interest, taxes and amortization|TScan - Operating profit EBITDA|Operating income before deduction of amortization Champions Oncology CSBR|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CVM|Operating profit before deduction of amortization OSTX|RADX (radiopharmtheranostics.com) - Company profit before taxes, interest and amortization|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|ANL (adlainortye.com) - Income before deduction of interest, taxes and amortization|Veru Pharma - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization TPST (Tempest Therapeutics Corp)|Xilio - Operating profit EBITDA|Income before deduction of interest, taxes and amortization RENB (Renovaro Inc.)|MURA: Operating profit EBITDA|Profit before interest, taxes and amortization Kairos Pharma (KAPA)|Profit before payment of interest, taxes and amortization OnKure Therapeutics, Inc.|GDTC: Income before deduction of interest, taxes and amortization|Operating profit EBITDA CRIS|Operating profit EBITDA apollomicsinc.com (APLM)|Profit before payment of interest, taxes and amortization Tharimmune THAR|ADVB (Advanced Biomed Inc.) - Profit before deduction of interest, taxes, depreciation and amortization|Genprex, Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Calidi Biotherapeutics|SBFM (Sunshine Biopharma, Inc.) - Operating profit before deduction of amortization|Xenetic Biosciences, Inc. (XBIO) - Operating profit EBITDA|Operating profit before deduction of amortization SLRX|PPBT (Purple Biotech Ltd) - Company profit before taxes, interest and amortization|Operating profit EBITDA AONC|Operating income before deduction of amortization BeiGene Ltd|Operating profit EBITDA ELEV (Elevation Oncology)|ICAD - Operating profit before deduction of amortization|IKNA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Notable Labs Ltd NTBL|VIRX: Operating profit EBITDA|Operating profit before deduction of amortization MorphoSys Corporation|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit EBITDA ascentage.com
